Close
Close

La Jolla Pharmaceutical Company - Catecholamine Resistant Hypotension (CRH)

Partner

Not provided

Rare Disease

Catecholamine Resistant Hypotension (CRH)

Sponsor

La Jolla Pharmaceutical Company

Access Program Information

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Contact

Contact: Tammy G Boyce (619-933-7176)

Locations

Free Newsletter